511 - Activity of Sulbactam-durlobactam and Standard-of-Care Antibiotics against Acinetobacter baumannii-calcoaceticus complex isolates acquired from Hospitalized Patients in the United States (2023 – 2024)

Saturday, October 19, 2024

10:54 AM – 11:06 AM US PT

Location: 403 A

Co-Author(s)

EB

Ecem Buyukyanbolu, MD

Hartford Hospital
Hartford, Connecticut, United States
JA

Jill Argotsinger, PharmD, BCIDP

Clinical Pharmacy Specialist, Infectious Diseases
Advocate Lutheran General Hospital
Park Ridge, Illinois, United States
EB

Eric T. Beck, PhD

Clinical Laboratory Director - Microbiology
Department of Microbiology, ACL Laboratories
West Allis, Wisconsin, United States
RC

Robin R. Chamberland, PhD D(ABMM)

Saint Louis University School of Medicine
St. Louis, Missouri, United States
AC

Andrew E. Clark, PhD, D(ABMM)

Assistant Professor
University of Texas Southwestern Medical Center
Dallas, Texas, United States
PG

Philip Gialanella, BS MS

Assistant Director
Montefiore Medical Center, Albert Einstein College of Medicine
Bronx, New York, United States
ML

Matthew Loeb, n/a

Kansas University Medical Center
Kansas City, Kansas, United States
AS

Amy Sears, n/a

Kansas University Medical Center
Kansas City, Kansas, United States
Amanda Harrington, PhD

Director, Clinical Microbiological Laboratory
Loyola University Chicago
Maywood, Illinois, United States
Romney Humphries, PhD, D(ABMM), M(ASCP)

Division Director, Laboratory Medicine
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Wesley D. Kufel, Pharm.D., BCPS, BCIDP

Clinical Associate Professor
Binghamton University School of Pharmacy Sciences
Binghamton, NY, United States
SR

Scott W. Riddell, Ph.D.

Director, Clinical Microbiology
State University of New York Upstate Medical University
Syracuse, New York, United States
AM

A. Brian Mochon, PhD

University of Arizona College of Medicine
Phoenix, Arizona, United States
CV

Christine A. Vu, PharmD

Infectious diseases pharmacist
Jackson Memorial Hospital
Miami, Florida, United States
Lilian M. Abbo, MD, MBA (she/her/hers)

Professor of Infectious Diseases; Associate Chief Medical Officer in Infectious Diseases
University of Miami Miller School of Medicine, Jackson Health System
Aventura, FL, United States
OM

Octavio Martinez, Ph.D., ABMM

Director, Clinical Microbiology Laboratory
Jackson Health System/University of Miami
Miami, FL, United States
JM

Jamie Marino, PhD

Assistant Professor of Clinical Pathology and Laboratory Medicine
Weill Cornell Medicine
NY, New York, United States
Lars Westblade, PhD

Clinical Microbiology Laboratory Director/Associate Professor
Weill Cornell Medicine
New York, NY, United States
DN

David P. Nicolau, PharmD

Director
Hartford Hospital
Hartford, Connecticut, United States

Presenting Author(s)

Tomefa E. Asempa, PharmD

Associate Director
Hartford Hospital
Hartford, CT, United States

Slides

Disclosure(s):

Ecem Buyukyanbolu, MD: No financial relationships to disclose

Jill Argotsinger, PharmD, BCIDP: No financial relationships to disclose

Eric T. Beck, PhD: No financial relationships to disclose

Robin R. Chamberland, PhD D(ABMM): No financial relationships to disclose

Andrew E. Clark, PhD, D(ABMM): No financial relationships to disclose

Philip Gialanella, BS MS: No financial relationships to disclose

Matthew Loeb, n/a: No financial relationships to disclose

Amy Sears, n/a: No financial relationships to disclose

Amanda Harrington, PhD: Beckman Coulter: Advisor/Consultant; bioMeriuex: Advisor/Consultant, Grant/Research Support; Bio-Rad: Advisor/Consultant; Day Zero: Advisor/Consultant; Selux Diagnostics: Grant/Research Support

Romney Humphries, PhD, D(ABMM), M(ASCP): No financial relationships to disclose

Wesley D. Kufel, Pharm.D., BCPS, BCIDP: Merck & Co.: Grant/Research Support (); Shionogi, Inc: Grant/Research Support ()

Scott W. Riddell, Ph.D.: No financial relationships to disclose

A. Brian Mochon, PhD: No financial relationships to disclose

Christine A. Vu, PharmD: No financial relationships to disclose

Lilian M. Abbo, MD, MBA: No financial relationships to disclose

Octavio Martinez, Ph.D., ABMM: No financial relationships to disclose

Jamie Marino, PhD: No financial relationships to disclose

Lars Westblade, PhD: Accelerate Diagnostics, Inc: Grant/Research Support (); bioMerieux, Inc: Grant/Research Support (); Element Materials Technology: Grant/Research Support (); Hardy Diagnostics: Grant/Research Support (); Roche Molecular Systems, Inc.: Advisor/Consultant (), Grant/Research Support (); Selux Diagnostics, Inc.: Grant/Research Support (); Shionogi, Inc: Advisor/Consultant (); Talis Biomedical: Advisor/Consultant ()

David P. Nicolau, PharmD: CARB-X: Grant/Research Support; Innoviva: Grant/Research Support, Honoraria; Merck: Advisor/Consultant, Grant/Research Support, Honoraria; Pfizer: Advisor/Consultant, Grant/Research Support, Honoraria; Shionogi: Advisor/Consultant, Grant/Research Support, Honoraria; Venatorx: Grant/Research Support

Tomefa E. Asempa, PharmD: FDA/CDER: Grant/Research Support; Paratek: Grant/Research Support; Shionogi: Grant/Research Support; Spero: Grant/Research Support; VenatoRx: Grant/Research Support